Perivascular Inflammation in Pulmonary Arterial Hypertension
Autor: | Leon Chi, Wolfgang M. Kuebler, Yijie Hu, Neil M. Goldenberg |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty Chemokine vascular remodeling Inflammation Review 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Immune system Parenchyma pulmonary hypertension medicine Perivascular inflammation Animals Humans Secretion lcsh:QH301-705.5 Pulmonary Arterial Hypertension biology business.industry General Medicine medicine.disease Pulmonary hypertension Phenotype 030104 developmental biology lcsh:Biology (General) biology.protein Blood Vessels Cytokines Disease Susceptibility medicine.symptom Inflammation Mediators business Biomarkers |
Zdroj: | Cells Cells, Vol 9, Iss 2338, p 2338 (2020) |
ISSN: | 2073-4409 |
Popis: | Perivascular inflammation is a prominent pathologic feature in most animal models of pulmonary hypertension (PH) as well as in pulmonary arterial hypertension (PAH) patients. Accumulating evidence suggests a functional role of perivascular inflammation in the initiation and/or progression of PAH and pulmonary vascular remodeling. High levels of cytokines, chemokines, and inflammatory mediators can be detected in PAH patients and correlate with clinical outcome. Similarly, multiple immune cells, including neutrophils, macrophages, dendritic cells, mast cells, T lymphocytes, and B lymphocytes characteristically accumulate around pulmonary vessels in PAH. Concomitantly, vascular and parenchymal cells including endothelial cells, smooth muscle cells, and fibroblasts change their phenotype, resulting in altered sensitivity to inflammatory triggers and their enhanced capacity to stage inflammatory responses themselves, as well as the active secretion of cytokines and chemokines. The growing recognition of the interaction between inflammatory cells, vascular cells, and inflammatory mediators may provide important clues for the development of novel, safe, and effective immunotargeted therapies in PAH. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |